Promising medical value of
THAC drug candidates

Potential game changers for the treatment of T2DM

Its pipeline could lead to potential real game changers for patient care and disease management. THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.

THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).

THAC drug candidates have a unique and innovative mechanism of action. THAC drug candidates have a unique and innovative mechanism of action.

THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications; peripheral neuropathy is a severe complication for which there is no treatment available, e.g., diabetic foot wounds and amputations.

THAC drug candidates are expected to be game changers in the T2DM disease management

Based on its unique and innovative mechanism of action, our ALF-5755 drug candidate, in response to the unmet medical need claimed by healthcare authorities

Decreases the oral inflammation and restores the local redox balance

Restores healthy microbiota composition

Increases insulin sensitivity
(in different adapted mice models)

Decreases basal glycemia

Decreases fat mass / increases lean mass

Increases activity in aged-mice

Allows healthy aging

THAC invests in R&D and has a strong preclinical and clinical study program ongoing and planned. Different formulations are studied.

THAC is focused on T2DM treatment and prevention of severe complications

THAC envisions that, with its drug candidates having a unique and innovative mechanism of action to restore the composition of gut microbiota and to fight insulin resistance (the root cause of T2DM), a major breakthrough could be achieved for the treatment of T2DM patients, for the prevention of severe complications and for a paradigm of the disease management, allowing a healthy aging.

THAC drug candidates are expected to be prescribed on top of first line T2DM treatments, by oral and sub-cutaneous administrations.

THAC drug candidates are intended to significantly delay disease progression, decrease side-effects of other drugs, improve patient’s quality of life, delay premature death and prevent T2DM complications: i.e., peripheral neuropathy is a severe complication for which there is no treatment available (e.g., diabetic foot wounds and amputations).

Moreover, ALF-5755 has other potential indications in age-related diseases.

THAC assets are based on the discoveries by Prof. C. Bréchot et al. at INSERM in the 1990’s and further studied.

ALF-5755, a unique and innovative mechanism of action

THAC drug candidates have a unique intrinsic ROS scavenger action in the extracellular matrix of inflamed tissues, without entering into the cells. This action induces the restoration of the insulin sensitivity and cells glucose uptake. As a result, cell death is reduced and induces a complementary anti-inflammatory and anti-adiposity benefits with a drastic decrease of a specific chemokine which is known to be a driver for insulin resistance and adiposity.

Know more about the root cause of T2DM

A First-In-Class drug candidate for the treatment of T2DM and its severe complications

ALF-5755, the active ingredient of THAC drugs candidates is a recombinant human protein derived from a human endogenous C-type lectin. It is a first-in-class molecule which is already GMP produced, with a safety profile demonstrated through PK/Tox studies in animal models and a first-in-man after iv administration .

ALF-5755 is developed to modify the course of T2DM disease, to prevent a severe complication (peripheral neuropathy) and to change the game of patients care.

Know more about THAC’s first-in-class pipeline.

ALF-5755, a high potential to treat other age-related diseases

Aging is a natural process characterized by many cellular and molecular changes including inflammation and oxidative stress.

Though physiological, these asymptomatic changes eventually lead to the development of insulin-resistance, a major risk factor for age-related diseases. Insulin resistance starts early in life, is silent and asymptomatic for many years, may lead to severe complications and can cause premature death.
AS ALF-5755 has unique anti-inflammatory and anti-oxidative properties which tackle insulin resistance. Thanks to this mechanis of action, it has a high potential to treat other age-related diseases as well as T2DM related complications, for which inflammation, oxidation and insulin resistance are involved. This feature allows to highly differentiated THAC drug candidates compared to other drugs which lead numerous side effects and complications.

Know more about T2DM and its challenges

THAC promising drug candidate to prevent T2DM severe complications

T2DM severe complications are often the results of the progression of the disease, despite marketed drugs, and the continuous inflammation and oxidative process induce by aging in the body: ophthalmologic, cardiac, neurological, renal, neuropathy disorders, foot ulcers and amputations.

As ALF-5755 has a unique pleiotropic action of anti-inflammation, anti-oxidative and insulin sensitization, one of the causes of the complications, it can be assumed that the drug candidate could prevent T2DM severe complications, in contrast to other marketed drugs.
In particular, THAC drug candidate, ALF-5755, has the potentiel to prevent the diabetic neuropathy which is responsible to the diabetic wound, ulcers and amputations for which there is no treatment. Ongoing studies are ongoing in his field.
Moreover, thanks to its unique pleiotropic action, ALF-5755 could decrease the side effects induced by other marketed drugs when administrated on top of the first line drugs.

The Healthy Aging Company

Promising medical value ofTHAC drug candidatesPotential game changers for the treatment of T2DM